$5.40
0.00% day before yesterday
Nasdaq, Aug 30, 12:10 am CET
ISIN
US76029N1063
Symbol
REPL

Replimune Group, Inc. Stock price

$5.40
+1.65 44.00% 1M
-7.28 57.41% 6M
-6.71 55.41% YTD
-5.66 51.18% 1Y
-13.74 71.79% 3Y
-21.60 80.00% 5Y
-9.76 64.38% 10Y
-9.76 64.38% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.02 0.37%
ISIN
US76029N1063
Symbol
REPL
Industry

Key metrics

Basic
Market capitalization
$421.5m
Enterprise Value
$90.3m
Net debt
positive
Cash
$403.3m
Shares outstanding
77.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 51.7
EV/Sales
- | 11.1
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
75.4%
Return on Equity
-59.5%
ROCE
-71.9%
ROIC
-644.4%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $8.2m
EBITDA
$-292.3m | $-211.1m
EBIT
$-294.7m | $-240.7m
Net Income
$-280.2m | $-263.3m
Free Cash Flow
$-227.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-24.9% | 18.5%
EBIT
-24.6% | 8.0%
Net Income
-27.4% | -6.5%
Free Cash Flow
-18.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -2,587.5%
EBIT
-
Net
- | -3,226.3%
Free Cash Flow
-
More
EPS
$-3.1
FCF per Share
$-2.9
Short interest
46.2%
Employees
331
Rev per Employee
$0.0
Show more

Is Replimune Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Replimune Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Replimune Group, Inc. forecast:

7x Buy
47%
7x Hold
47%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Replimune Group, Inc. forecast:

Buy
47%
Hold
47%
Sell
7%

Financial data from Replimune Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 91 91
55% 55%
-
- Research and Development Expense 201 201
15% 15%
-
-292 -292
25% 25%
-
- Depreciation and Amortization 2.43 2.43
0% 0%
-
EBIT (Operating Income) EBIT -295 -295
25% 25%
-
Net Profit -280 -280
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Replimune Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Replimune Group, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options
Neutral
PRNewsWire
4 days ago
NEW YORK , Aug. 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
PRNewsWire
5 days ago
NEW YORK , Aug. 27, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purcha...
More Replimune Group, Inc. News

Company Profile

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Head office United States
CEO Sushil Patel
Employees 331
Founded 2015
Website www.replimune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today